1. Home
  2. DCTH vs ENGN Comparison

DCTH vs ENGN Comparison

Compare DCTH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.14

Market Cap

350.7M

Sector

Health Care

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$9.34

Market Cap

379.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCTH
ENGN
Founded
1988
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
350.7M
379.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DCTH
ENGN
Price
$10.14
$9.34
Analyst Decision
Strong Buy
Buy
Analyst Count
5
7
Target Price
$22.60
$22.71
AVG Volume (30 Days)
596.1K
283.0K
Earning Date
11-04-2025
12-22-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
$79,603,000.00
N/A
Revenue This Year
$131.97
N/A
Revenue Next Year
$38.84
N/A
P/E Ratio
$291.69
N/A
Revenue Growth
251.54
N/A
52 Week Low
$8.12
$2.65
52 Week High
$18.23
$11.14

Technical Indicators

Market Signals
Indicator
DCTH
ENGN
Relative Strength Index (RSI) 57.08 62.85
Support Level $9.84 $7.57
Resistance Level $10.44 $8.47
Average True Range (ATR) 0.43 0.69
MACD 0.03 0.07
Stochastic Oscillator 50.93 78.18

Price Performance

Historical Comparison
DCTH
ENGN

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: